It is known that overexpression of HER2 is found in about 20% of breast cancer patients, leading to aberrant signaling of the PI3K/Akt and MEK/Erk pathways, and is correlated with malignant transformation, chemotherapy resistance and poor prognosis.1, 6, 7 Meanwhile, aberrant EGFR activity was also observed during pathogenesis and progression of lung and breast cancers.8, 9 Therefore, a promising approach may lie in the development of chemotherapeutic strategies exploiting the deregulation of target ERBB to create cancer treatments with both preventive and therapeutic potential. Here, EGFR is linked to breast carcinoma.